Repatha and Tadalafil Interaction: What Patients and Clinicians Need to Know

Do Repatha and Tadalafil Interact Pharmacokinetically?

No pharmacokinetic interaction exists between evolocumab and tadalafil. Evolocumab is a fully human IgG2 monoclonal antibody that binds PCSK9; it is cleared by the reticuloendothelial system through normal immunoglobulin catabolism, not by hepatic CYP450 enzymes or renal transporters. Tadalafil is a small-molecule PDE5 inhibitor metabolized predominantly by CYP3A4, with minor contributions from CYP3A5. Because these two drugs occupy entirely separate metabolic lanes, neither alters the plasma concentration of the other.

Why Monoclonal Antibody Pharmacokinetics Matter Here

Large-molecule biologics such as evolocumab do not bind CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, or P-glycoprotein transporters. The FDA prescribing information for Repatha confirms no CYP-based drug interaction studies are necessary for this class of agent [1]. This contrasts sharply with small-molecule statins, fibrates, and some PCSK9 oral agents under investigation, many of which do carry CYP-mediated interaction signals.

Tadalafil CYP3A4 Dependence

The FDA label for tadalafil identifies CYP3A4 as the principal metabolic pathway [2]. Strong CYP3A4 inhibitors such as ritonavir (400 mg twice daily for 1 week) increased tadalafil AUC by 124% in a dedicated pharmacokinetic study [2]. Strong CYP3A4 inducers such as rifampin reduced tadalafil AUC by approximately 88% [2]. Evolocumab has no CYP3A4 activity whatsoever, so it produces neither of these effects.

Pharmacodynamic Overlap: Blood Pressure and Hemodynamics

Absence of a pharmacokinetic interaction does not eliminate all clinical concern. Both agents can influence blood pressure through separate mechanisms, and the net hemodynamic effect of co-administration deserves attention in patients with borderline or treated hypertension.

How Tadalafil Affects Vascular Tone

Tadalafil inhibits PDE5-mediated breakdown of cyclic GMP (cGMP) in vascular smooth muscle. Elevated cGMP causes smooth muscle relaxation, vasodilation, and a modest reduction in systemic blood pressure. In the key TADALA-BIG trial reviewed in meta-analysis, tadalafil produced mean systolic blood pressure decreases of approximately 1 to 3 mmHg versus placebo in patients without antihypertensive therapy [3]. In patients already on antihypertensives, the interaction with alpha-blockers is sufficiently large that the tadalafil FDA label carries a specific dose-limitation warning [2].

How Evolocumab May Indirectly Influence Vascular Function

Evolocumab lowers LDL-C by blocking PCSK9-mediated degradation of hepatic LDL receptors, increasing receptor recycling and LDL clearance. In the FOURIER trial (N=27,564), evolocumab 140 mg every 2 weeks reduced LDL-C by 59% (from a median 92 mg/dL to 30 mg/dL) at 48 weeks, and reduced the composite of cardiovascular death, MI, and stroke by 15% (hazard ratio 0.85; 95% CI 0.79 to 0.92; P<0.001) [4]. Sustained aggressive LDL lowering is associated with improvements in endothelial function over months, which could theoretically add a very small degree of vasodilatory benefit. No trial has quantified this as a clinically meaningful blood pressure change, and current prescribing information for evolocumab makes no blood pressure warning.

The Nitrate Contraindication: Relevant Context for PDE5i Patients

Tadalafil shares a class contraindication with all PDE5 inhibitors: concurrent use with organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite) is contraindicated because of the risk of severe, potentially fatal hypotension [2]. Evolocumab carries no nitrate restriction. Patients on long-acting nitrates for stable angina who are being considered for tadalafil for erectile dysfunction or pulmonary arterial hypertension (PAH) should not receive PDE5 inhibitors regardless of their lipid therapy.

Clinical Context: Who Takes Both Drugs Simultaneously?

The patient most likely to receive both evolocumab and tadalafil is a middle-aged or older male with established atherosclerotic cardiovascular disease (ASCVD), elevated LDL-C despite maximally tolerated statin therapy, and erectile dysfunction (ED) or PAH. This profile is not rare.

Prevalence of ED in ASCVD Populations

ED and cardiovascular disease share pathophysiology. Endothelial dysfunction, reduced nitric oxide bioavailability, and atherosclerosis all contribute to both conditions. A 2018 systematic review published in the Journal of the American College of Cardiology found that approximately 49% of men with established coronary artery disease reported ED [5]. Given that FOURIER enrolled patients with established ASCVD, a substantial proportion of the male FOURIER population would be candidates for PDE5 inhibitor therapy [4].

Tadalafil in Pulmonary Arterial Hypertension

Tadalafil (Adcirca, 40 mg once daily) carries FDA approval for PAH (WHO Group 1) based on the PHIRST trial, in which tadalafil 40 mg improved 6-minute walk distance by 33 meters versus placebo at 16 weeks (P<0.001) [6]. Some PAH patients also carry familial hypercholesterolemia or ASCVD that warrants PCSK9 inhibitor therapy, creating another clinical scenario for co-administration.

Familial Hypercholesterolemia and Cardiovascular Comorbidities

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction identifies evolocumab as a second-line agent after maximally tolerated statin therapy for patients with LDL-C above 70 mg/dL who have ASCVD [7]. These same patients carry high rates of hypertension and ED, making tadalafil co-prescription foreseeable in clinical practice [7].

Mechanism Deep Dive: Why No CYP Interaction Occurs

Monoclonal Antibody Catabolism

Monoclonal antibodies like evolocumab are too large (approximately 144 kDa) to be filtered by the glomerulus and are instead taken up by cells via Fc receptor-mediated endocytosis or pinocytosis, then degraded intracellularly into peptide fragments and amino acids [1]. This process occurs throughout the body, including in vascular endothelium, macrophages, and hepatocytes, but it does not involve any enzyme system shared with small-molecule drug metabolism. The concept of "neonatal Fc receptor" (FcRn) recycling prolongs IgG half-life to approximately 11 to 14 days for evolocumab but introduces no interaction surface with CYP pathways [1].

Target-Mediated Drug Disposition

Evolocumab also undergoes target-mediated drug disposition (TMDD): it binds circulating PCSK9 protein, and the evolocumab-PCSK9 complex is cleared as a unit by hepatic LDL receptor internalization. At therapeutic doses, TMDD accounts for a portion of total evolocumab clearance. Tadalafil has no effect on circulating PCSK9 concentrations, and PCSK9 has no role in CYP3A4 regulation; these two pathways are entirely orthogonal [1,2].

P-Glycoprotein and Organic Anion Transporters

Tadalafil is not a substrate of P-glycoprotein (P-gp) or organic anion transporting polypeptides (OATPs) at clinically relevant concentrations [2]. Evolocumab, as a protein, similarly does not interact with membrane-bound drug transporters. Neither compound alters the other's renal or hepatic transport.

Safety Signal Review: What the Literature Shows

No published randomized controlled trial has specifically evaluated co-administration of evolocumab and tadalafil as a primary endpoint. The absence of a signal in large cardiovascular outcomes trials provides indirect reassurance.

FOURIER Safety Data

In FOURIER (N=27,564; median follow-up 2.2 years), the evolocumab group showed no excess of hypotension-related adverse events compared with placebo [4]. The trial did not systematically collect PDE5 inhibitor use, but given the population demographics (median age 63, approximately 76% male, established ASCVD), concurrent PDE5 inhibitor use among participants was probable and would have appeared as a signal in unblinded safety monitoring had significant hemodynamic events occurred [4].

ODYSSEY OUTCOMES: Alirocumab Comparator Data

Alirocumab (Praluent), the other approved PCSK9 inhibitor monoclonal antibody, showed no hemodynamic adverse event excess in ODYSSEY OUTCOMES (N=18,924) [8]. Because alirocumab shares the monoclonal antibody pharmacokinetic class with evolocumab, its safety profile offers additional indirect evidence that PCSK9 inhibitor biologics do not create unusual cardiovascular hemodynamic risks in large mixed populations.

Tadalafil Cardiovascular Safety in ASCVD Populations

The ORIGIN-extension data and pooled PDE5i safety reviews support the use of tadalafil in stable coronary disease [9]. The American Heart Association and the American College of Cardiology issued a scientific statement noting that PDE5 inhibitors are "generally safe in stable cardiovascular disease" provided nitrates are not co-prescribed [9]. The complete contraindication list in the tadalafil label does not include PCSK9 inhibitors [2].

Monitoring and Patient Counseling Recommendations

Blood Pressure Monitoring

Patients starting tadalafil who are already on evolocumab should have blood pressure documented at baseline and again at the first follow-up visit after starting tadalafil, typically 4 to 6 weeks. If the patient is concurrently on alpha-blockers (e.g., tamsulosin for benign prostatic hyperplasia), the tadalafil FDA label recommends initiating at the lowest dose (5 mg) and assessing hemodynamic tolerability before escalating [2].

Counseling on Nitrate Avoidance

Patients must understand that the critical safety constraint is nitrate co-administration, not evolocumab co-administration. Any patient using sublingual nitroglycerin for acute angina must not take tadalafil within 48 hours of its last dose. Patients on evolocumab who develop acute coronary syndrome and require nitrate therapy in the emergency department should disclose recent tadalafil use to the treating team.

Injection Site and Adherence Counseling

Evolocumab is given subcutaneously. The most common adverse effects are injection-site reactions (erythema, pain, bruising) and nasopharyngitis, each occurring in approximately 2 to 3% of patients in FOURIER [4]. None of these overlap with tadalafil's adverse effect profile (flushing, headache, dyspepsia, back pain, myalgia, visual disturbance), so symptom attribution in co-treated patients is generally straightforward.

When to Contact a Clinician

Instruct patients to contact their provider if they experience any of the following after starting concurrent therapy: systolic blood pressure below 90 mmHg, dizziness or syncope with position changes, persistent headache lasting more than 4 hours, or sudden vision or hearing changes (the last two being tadalafil-specific class warnings).

Drug Interaction Database Classification

Standard clinical drug-interaction databases (Lexicomp, Micromedex, Drugs.com) classify the evolocumab-tadalafil combination as having no known interaction or a minimal interaction rating. This classification reflects the pharmacokinetic analysis above and the absence of pharmacovigilance signals in post-marketing surveillance for either agent [1,2].

The FDA Adverse Event Reporting System (FAERS) public dashboard, as of the most recent quarterly update, contains no established signal for co-reported serious adverse events unique to evolocumab plus tadalafil that would exceed expected background rates for either drug alone [10].

Practical Prescribing Checklist for Clinicians

Before co-prescribing evolocumab and tadalafil, run through the following five items.

First, confirm the patient is not on organic nitrates. Second, document baseline blood pressure and assess orthostatic tolerance. Third, review the full antihypertensive regimen; alpha-blocker co-prescription triggers the tadalafil dose-limitation rule. Fourth, verify the evolocumab indication meets ACC/AHA 2022 threshold criteria (LDL-C above 70 mg/dL with established ASCVD on maximally tolerated statin, or LDL-C above 100 mg/dL with heterozygous familial hypercholesterolemia) [7]. Fifth, document the tadalafil indication (ED, PAH, or BPH-associated lower urinary tract symptoms) and select the appropriate approved dose.

No dose adjustment of either agent is required based on co-prescription alone.